ORIGINAL ARTICLE
Year : 2016 | Volume
: 10 | Issue : 3 | Page : 97--101
Pure tone audiometric findings in patients on second-line treatment for multidrug-resistant tuberculosis
Matilda Uju Ibekwe, Chibuike Nwosu Department of ENT Surgery, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria
Correspondence Address:
Matilda Uju Ibekwe Department of ENT Surgery, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State Nigeria
Background: The need for second-line antitubercular medication has been on the increase due to the emergence of multidrug-resistant strain tuberculosis (MDR-TB) in our environment.
Aim: This study was to assess the effect of second-line antitubercular medication on hearing in patients with MDR-TB.
Patients and Methods: This is a prospective study of all the patients admitted to the MDR-TB center of the University of Port Harcourt Teaching Hospital between January and May 2013. All patients had pure tone audiometry done before and 3 months after commencement of second-line antitubercular medications. The second-line regimen used includes kanamycin, levofloxacin, cycloserine, pyrazinamide, and pyridoxine.
Results: The study had a total of 28 patients. There were 14 males and 14 females. The age range was between 18 and 68 years. Different degrees of high-frequency sensorineural hearing loss (SNHL) were seen in 14 patients after 3 months' therapy. There were 13 bilateral and 1 unilateral hearing impairment, 2 patients had profound SNHL. However, a good number had involvement of the speech frequencies.
Conclusion: Second-line antitubercular medication appears to have a tremendous effect on hearing. This raises a public health issue since there is a growing increase in MDR-TB in our environment.
How to cite this article:
Ibekwe MU, Nwosu C. Pure tone audiometric findings in patients on second-line treatment for multidrug-resistant tuberculosis.Port Harcourt Med J 2016;10:97-101
|
How to cite this URL:
Ibekwe MU, Nwosu C. Pure tone audiometric findings in patients on second-line treatment for multidrug-resistant tuberculosis. Port Harcourt Med J [serial online] 2016 [cited 2024 Mar 29 ];10:97-101
Available from: https://www.phmj.org/article.asp?issn=0795-3038;year=2016;volume=10;issue=3;spage=97;epage=101;aulast=Ibekwe;type=0 |
|
|